Deferoxamine Mesylate
作者：齊岳
發(fā)布時間：2023-09-13
09:11:08
點擊數(shù)：
產(chǎn)品名稱：Deferoxamine Mesylate
產(chǎn)品描述：
| 產(chǎn)品描述 | Deferoxamine is an iron-chelating agent that binds free iron in a stable complex. It also is an inhibitor of ferroptosis. |
| 體外活性 | Deferoxamine (DFO) had growth-arresting and apoptosis-inducing effect on TAMSCs and bone marrow MSCs (BMMSCs). DFO also influenced the expression pattern of adhesion molecule VCAM-1 on both TAMSCs and BMMSCs [1]. LLC-PK(1) cells were exposed to hypoxia, stimulated with desferrioxamine (Deferoxamine). Although all stimuli elicited HIF-1alpha stabilization with differences in the time-dependent accumulation pattern, significant variations appeared with regard to signaling [2]. No significant differences could be seen between AdMSC seeded collagen-GAG that was exposed to 1% O2 and 120?μM DFO. Cells exposed to 30 or 60?μM of DFO showed lower expression of HIF-1α [3]. |
| 體內(nèi)活性 | The rats were treated with deferoxamine (DFX) or vehicle (100mg/kg) for a maximum of 7 days. In SAH rat, the peak time of brain edema and BBB impairment in the cortex was at day 3 after SAH. SAH resulted in a significant increase in ferritin expression in the cortex. The ferritin positive cells were colocalized with endothelial cells, pericytes, astrocytes, microglia, and neurons [4]. Mice were treated 3x/week with 0.24 C intranasal (IN) DFO for 18 weeks from 36 to 54 weeks of age. IN DFO treatment significantly decreased loss of both reference and working memory in the Morris and radial arm water mazes, and also decreased soluble Aβ40 and Aβ42 in cortex and hippocampus. Further, IN DFO decreased activity of GSK3β, and led to decreases in oxidative stress [5]. |
| 細(xì)胞實驗 | After cells were seeded onto the collagen-GAG discs and allowed to adhere for 3?hours, they were placed into a hypoxic incubator with 1% O2 or incubated under standard cell culture conditions with deferoxamine mesylate (DFO) added to final concentrations of 30, 60, or 120?μM. Scaffolds seeded with AdMSCs cultured under standard conditions were used as a control [3]. |
| 動物實驗 | The animals were divided into 4 groups: sham, SAH, SAH+vehicle and SAH+DFX (100mg/kg) group. DFX was administered intraperitoneally 2 and 6 hours after hemorrhage followed by every 12 hours for a maximum of 7 days. The same time course and dosage of saline were administered in the SAH+vehicle group. Afterward, rats underwent behavioral testing and were euthanized at day 1, 3, 7 and 28 for brain water content calculation, immunohistochemistry or western blot assays. The study was performed in three parts. Part 1 measured the brain water content, Evan's blue extravasation, and ultrastructural abnormalities at day 1, 3 and 7 after SAH to evaluate the time-dependent changes in brain edema and BBB disruption (n = 4 per time point and group). Part 2 investigated the role of iron in SAH-induced BBB disruption at day 1, 3 and 7 by brain water content (n = 4, per time point and group), Evan's blue extravasation (n = 4, per time point and group), transmission electron microscopy (n = 4, per time point and group), immunohistochemistry (n = 4, per time point and group) and western blot analysis (n = 3, per time point and group). Part 3 compared the acute (n = 61, per group at day 1; n = 42, per group at day 3; n = 23, per group at day 7) and long term (n = 4, per group at day 28) neurological function after SAH in each group to determine the effect of iron chelation on SAH-induced neurologic impairment [4]. |
| 別名 | desferrioxamine B, 去鐵銨, Desferrioxamine B mesylate, 甲磺酸去鐵胺, DFOM |
| 化合物與蛋白結(jié)合的復(fù)合物 |
Crystal structure of ferric R-state human methemoglobin bound to maleimide-deferoxamine bifunctional chelator (DFO) |
| 分子量 | 656.79 |
| 分子式 | C26H52N6O11S |
| CAS No. | 138-14-7 |
存儲
| Powder: -20°C for 3 years | In solvent: -80°C for 2 years
溶解度
DMSO: 152.3 mM
H2O: 20.83 mg/mL (31.72 mM)
( < 1 mg/mL refers to the product slightly soluble or insoluble )
聯(lián)系我們：
郵箱：2519696869@qq.com
QQ: 2519696869
電話：18066853083
微信：18066853083
公司介紹：
西安齊岳生物科技有限公司是集化學(xué)科研和定制與一體的高科技化學(xué)公司。業(yè)務(wù)范圍包括化學(xué)試劑和產(chǎn)品的研發(fā)、生產(chǎn)、銷售等。涉及產(chǎn)品為通用試劑的分銷、非通用試劑的定制與研發(fā)，涵蓋生物科技、化學(xué)品、中間體和化工材料等領(lǐng)域。
主營產(chǎn)品：COF、MOF單體系列：三蝶烯衍生物、金剛烷衍生物、四苯甲烷衍生物、peg、上轉(zhuǎn)換、石墨烯、光電材料、點擊化學(xué)、凝集素、載玻片、蛋白質(zhì)交聯(lián)劑、脂質(zhì)體、蛋白、多肽、氨基酸、糖化學(xué)等。
